Jessica L Fairley , Laura Ross , Elizabeth Paratz , Penelope McKelvie , Dylan Hansen MBiostatistics , Wendy Stevens , Andre La Gerche , Mandana Nikpour
{"title":"Pathological contributors to organ damage and mortality in systemic sclerosis: a nationwide matched case-control study","authors":"Jessica L Fairley , Laura Ross , Elizabeth Paratz , Penelope McKelvie , Dylan Hansen MBiostatistics , Wendy Stevens , Andre La Gerche , Mandana Nikpour","doi":"10.1016/j.semarthrit.2025.152739","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Mortality is increased in systemic sclerosis (SSc), including a 10–15-fold increase in sudden cardiac death. Limited histopathology data exist to understand the pathogenesis of this excess. This study aimed to compare heart, lung and renal histopathology at autopsy between SSc and controls.</div></div><div><h3>Methods</h3><div>A matched case-control study was performed using autopsy data from the Australian National Coronial Information System. SSc cases were selected via keyword search, and age- and sex-matched to controls identified from motor vehicle accidents. Cause of death, antemortem comorbidities and autopsy findings were extracted. Odds ratios were calculated with 95 % confidence intervals (CI).</div></div><div><h3>Findings</h3><div>Fifty-nine SSc cases (64 years, 81 % female) were matched to 59 controls (62 years, 81 % female). Myocardial fibrosis was 11-times more common in SSc (95 %CI 4–29, <em>p</em> < 0.01), inflammation 39-times more common (95 %CI 2–672, <em>p</em> = 0.01) and small vessel vasculopathy 27-times more common (95 %CI 2–485, <em>p</em> = 0.02), despite no difference in epicardial coronary artery disease (<em>p</em> = 0.24). Two-thirds of SSc cases had myocardial fibrosis with no identifiable secondary cause (e.g., coronary/valvular lesions). Pulmonary fibrosis, inflammation and vasculopathy ranged from 23 to 100-times more common in SSc. Renal fibrosis/scarring, inflammation/infiltrates and vasculopathy were 3–6-times more common in SSc. Among SSc cases, combined pathologies (≥2 of fibrosis, inflammation or vasculopathy) were seen concurrently in 31 % of hearts, 41 % of lungs and 45 % of kidneys.</div></div><div><h3>Interpretation</h3><div>The high frequency of unexplained myocardial fibrosis in SSc provides insights into the mechanism of excess mortality and sudden cardiac death observed in SSc. This matched autopsy study demonstrates the mechanisms and complexity of organ damage in SSc, with 30–45 % of organs displaying multiple concurrent pathologies.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152739"},"PeriodicalIF":4.6000,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in arthritis and rheumatism","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0049017225001106","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Mortality is increased in systemic sclerosis (SSc), including a 10–15-fold increase in sudden cardiac death. Limited histopathology data exist to understand the pathogenesis of this excess. This study aimed to compare heart, lung and renal histopathology at autopsy between SSc and controls.
Methods
A matched case-control study was performed using autopsy data from the Australian National Coronial Information System. SSc cases were selected via keyword search, and age- and sex-matched to controls identified from motor vehicle accidents. Cause of death, antemortem comorbidities and autopsy findings were extracted. Odds ratios were calculated with 95 % confidence intervals (CI).
Findings
Fifty-nine SSc cases (64 years, 81 % female) were matched to 59 controls (62 years, 81 % female). Myocardial fibrosis was 11-times more common in SSc (95 %CI 4–29, p < 0.01), inflammation 39-times more common (95 %CI 2–672, p = 0.01) and small vessel vasculopathy 27-times more common (95 %CI 2–485, p = 0.02), despite no difference in epicardial coronary artery disease (p = 0.24). Two-thirds of SSc cases had myocardial fibrosis with no identifiable secondary cause (e.g., coronary/valvular lesions). Pulmonary fibrosis, inflammation and vasculopathy ranged from 23 to 100-times more common in SSc. Renal fibrosis/scarring, inflammation/infiltrates and vasculopathy were 3–6-times more common in SSc. Among SSc cases, combined pathologies (≥2 of fibrosis, inflammation or vasculopathy) were seen concurrently in 31 % of hearts, 41 % of lungs and 45 % of kidneys.
Interpretation
The high frequency of unexplained myocardial fibrosis in SSc provides insights into the mechanism of excess mortality and sudden cardiac death observed in SSc. This matched autopsy study demonstrates the mechanisms and complexity of organ damage in SSc, with 30–45 % of organs displaying multiple concurrent pathologies.
背景:系统性硬化症(SSc)的死亡率增加,其中心源性猝死增加10 - 15倍。有限的组织病理学数据存在,以了解这种过量的发病机制。本研究旨在比较SSc和对照组尸检时的心脏、肺和肾脏组织病理学。方法采用澳大利亚国家冠状信息系统的尸检数据进行匹配病例对照研究。通过关键词搜索选择SSc病例,并将年龄和性别与从机动车事故中确定的对照组相匹配。提取了死亡原因、死前合并症和尸检结果。比值比以95%置信区间(CI)计算。59例SSc患者(64岁,81%为女性)与59例对照组(62岁,81%为女性)相匹配。心肌纤维化在SSc中发生率是前者的11倍(95% CI 4-29, p <;尽管心外膜冠状动脉疾病没有差异(p = 0.24),但炎症的发生率是前者的39倍(95% CI 2-672, p = 0.01),小血管病变的发生率是后者的27倍(95% CI 2-485, p = 0.02)。三分之二的SSc病例有心肌纤维化,没有明确的继发原因(如冠状动脉/瓣膜病变)。肺纤维化、炎症和血管病变在SSc中是前者的23 - 100倍。肾纤维化/瘢痕、炎症/浸润和血管病变是SSc的3 - 6倍。在SSc病例中,31%的心脏、41%的肺部和45%的肾脏同时出现合并病理(≥2种纤维化、炎症或血管病变)。SSc中高频率的不明原因心肌纤维化为SSc中观察到的过度死亡率和心源性猝死的机制提供了见解。这项匹配的尸检研究证明了SSc中器官损伤的机制和复杂性,30 - 45%的器官表现出多种并发病变。
期刊介绍:
Seminars in Arthritis and Rheumatism provides access to the highest-quality clinical, therapeutic and translational research about arthritis, rheumatology and musculoskeletal disorders that affect the joints and connective tissue. Each bimonthly issue includes articles giving you the latest diagnostic criteria, consensus statements, systematic reviews and meta-analyses as well as clinical and translational research studies. Read this journal for the latest groundbreaking research and to gain insights from scientists and clinicians on the management and treatment of musculoskeletal and autoimmune rheumatologic diseases. The journal is of interest to rheumatologists, orthopedic surgeons, internal medicine physicians, immunologists and specialists in bone and mineral metabolism.